SC 0806

Drug Profile

SC 0806

Alternative Names: heparin-activated recombinant human fibroblast growth factor 1; rhFGF1; SC0806

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Swenora Biotech
  • Developer BioArctic
  • Class Fibroblast growth factors; Neuroprotectants
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Spinal cord injuries

Most Recent Events

  • 28 Aug 2017 SC 0806 is still in phase I/II trials for Spinal chord injuries (In adults, In the elderly) in Sweden (Intrathecal) (NCT02490501) (EudraCT2013-000906-52)
  • 24 Mar 2015 Phase-I/II clinical trials in Spinal cord injuries (In adults, In the elderly) in Sweden (Intrathecal) (EudraCT2013-000906-52)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top